Pictet North America Advisors 13F: New $719K Stake in ABBV
Key Points
- Pictet North America Advisors opened a new position in AbbVie Inc. with 2,747 shares valued at approximately $718,588 on October 21, 2026.
- AbbVie shares trade near their 52-week high of $291.40, recently changing hands around $289.08.
- Several institutional investors and analysts adjusted their views on the biopharmaceutical firm ahead of its October 30, 2026 earnings release.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Pictet North America Advisors opened a new position in AbbVie Inc. (NYSE: ABBV), acquiring 2,747 shares valued at roughly $718,588. The investment was revealed in a Form 13F filing submitted to the Securities and Exchange Commission on October 21, 2026. AbbVie closed at $284.80 on the day of the filing.
ABBV
AbbVie Inc.
What Changed in Pictet North America Advisors's AbbVie Position
The firm established a brand-new stake in the biopharmaceutical company during the period, entering the quarter with zero shares and finishing with 2,747 shares. The reported value of the holdings reached $718,588.
Other Institutional Activity in AbbVie
Other institutional investors also adjusted their portfolios around the stock. AlphaStar Capital Management grew its holdings by 2,299 shares, ending with 19,380 shares worth about $5.06 million. Y-Intercept sold out its entire stake, unloading 74,248 shares. Kmg Fiduciary Partners trimmed its holdings by 2,381 shares, leaving it with 60,697 shares valued at about $15.88 million. Zwj Investment Counsel reduced its position by 6,901 shares to finish with 334,519 shares worth roughly $87.51 million. Trexquant Investment cut its stake by 18,177 shares, holding 77,280 shares valued at about $19.52 million.
AbbVie Inc. Stock Down 0.2%
AbbVie shares recently traded around $290.00, sitting near the peak of their 52-week range.
Recent Earnings
AbbVie posted revenue and net income totals reflecting its drug development portfolio.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
Eligible shareholders receive an annual payout backed by the company's cash flow.
Insider Buying and Selling at AbbVie Inc.
Company insiders executed several stock transactions earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares on February 25, 2026, at an average price of $230.00 for a total value of $5,147,630. Siatis later sold 18,668 shares on March 2, 2026, valued at $4,375,549. Officer David Ryan Purdue sold 5,230 shares on March 4, 2026, at an average price of $233.56, totaling $1,221,519. Officer Nicholas Donoghoe sold 32,710 shares on August 14, 2026, at an average price of $250.00, worth $8,177,500.
Analysts Set New Price Targets
Wall Street firms updated their outlooks on the stock through October. JP Morgan maintained an Overweight rating on October 8, 2026, raising its target from $285.00 to $300.00. UBS kept a Neutral rating on October 9, 2026, lifting its target from $260.00 to $275.00. Guggenheim reiterated a Buy rating on October 9, 2026, with a target of $288.00.
About AbbVie
AbbVie Inc. is a research-focused healthcare enterprise that discovers, develops, and markets advanced therapies for complex medical conditions. The firm specializes in immunology, oncology, and neuroscience treatments distributed to patients around the globe.
Bottom Line
Investors are now looking toward AbbVie's upcoming financial results scheduled for October 30, 2026. The report will offer fresh insight into sales trends for key drugs and overall operational progress.
Related Filing Alerts
Source: Pictet North America Advisors's 13F filing on $ABBV (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts